TRANSLATIONAL MEDICINE: DEFINITION, HISTORY, AND STRATEGIES

• Published in: Translational Medicine and Drug Discovery pp. 3 - 34
• Main Author: Littman, Bruce H.
• Format: Book Chapter
• Language: English
• Published: Cambridge University Press 31.01.2011
• Subjects: Pharmaceuticals; Pharmaceuticals, Cosmetics & Toiletries
• ISBN: 9780521886451; 9781107435940; 1107435943; 0521886457
• DOI: 10.1017/CBO9780511976087.003

What is translational medicine? This discipline, although defined differently by various groups in academia, regulatory institutions, and industry, shares the fundamental vision of translational medicine, which is to efficiently and effectively translate basic scientific findings relevant to human disease into knowledge that benefits patients. Pfizer was one of the first pharmaceutical companies to embrace experimental medicine and translational medicine as a recognized discipline within the sphere of early drug development, and this author was intimately involved in the evolution of this discipline since its inception at this company. This chapter therefore describes the significance, role, and practice of translational medicine in drug development from a Pfizer perspective, although the concepts are considered to be widely applicable to drug development at any academic, public, or private institution. At Pfizer, translational medicine was defined as “the integrated application of innovative pharmacology tools, biomarkers, clinical methods, clinical technologies, and study designs to improve confidence in human drug targets and increase confidence in drug candidates, understand the therapeutic index in humans, enhance cost-effective decision making in exploratory development, and increase success in Phase 2 leading to a sustainable pipeline of new products.” Because this book focuses on drug development, this will be the definition for the purposes of this chapter.In the late 1980s and early 1990s, pharmaceutical companies were rapidly adopting a drug discovery strategy that depended on selecting drug targets based on what was known about key pathways important in disease expression, enzymes that catalyzed rate-limiting steps along the pathway, or cellular receptors that were ligated by important relevant mediators.